T Heusner

Correlation of the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in Hybrid 18F-FDG PET/MRI in Non-Small Cell Lung Cancer (NSCLC) Lesions: Initial Results

PURPOSE To compare the apparent diffusion coefficient (ADC) in non-small cell lung cancer lesions with standardized uptake values (SUV) derived from combined 18F-fluoro-deoxy-glucose-positron emission tomography/magnetic resonance imaging (FDG-PET/MRI) and those derived from FDG-PET/CT. MATERIALS AND METHODS In 18 consecutive patients with histologically proven NSCLC (17 men, 1 woman; mean age, 61 ± 12 years), whole-body FDG-PET/MRI was performed after whole-body FDG-PET/CT. Regions of interest (ROI) encompassing the entire primary tumor were drawn into FDG-PET/CT and FDG-PET/MR images to determine the maximum and mean standardized uptake value (SUVmax; SUVmean) and into ADC parameter maps to assess mean ADC values. Pearsons correlation coefficients were calculated to compare SUV and ADC values. RESULTS The SUVmax of NSCLC was 12.3 ± 4.8 [mean ±SD], and the SUVmean was 7.2 ± 2.8 as assessed by FDG-PET/MRI. The SUVmax and SUVmean derived from FDG-PET/CT and FDG-PET/MRI correlated well (R = 0.93; p < 0.001 and R = 0.92; p < 0.001, respectively). The ADCmean of the pulmonary tumors was 187.9 ± 88.8 × 10-5 mm²/s [mean ± SD]. The ADCmean exhibited a significant inverse correlation with the SUVmax (R = -0.72; p < 0.001) as well as with the SUVmean assessed by FDG-PET/MRI (R = -0.71; p < 0.001). CONCLUSION This simultaneous PET/MRI study corroborates the assumed significant inverse correlation between increased metabolic activity on FDG-PET and restricted diffusion on DWI in NSCLC.Citation Format:

Positron emission tomography (PET) attenuation correction artefacts in PET/CT and PET/MRI

OBJECTIVE To compare the effect of implanted medical materials on (18)F-fludeoxyglucose ((18)F-FDG) positron emission tomography (PET)/MRI using a Dixon-based segmentation method for MRI-based attenuation correction (MRAC), PET/CT and CT-based attenuation-corrected PET (PETCTAC). METHODS 12 patients (8 males and 4 females; age 58±11 years) with implanted medical materials prospectively underwent whole-body (18)F-FDG PET/CT and PET/MRI. CT, MRI and MRAC maps as well as PETCTAC and PETMRAC images were reviewed for the presence of artefacts. Their morphology and effect on the estimation of the (18)F-FDG uptake (no effect, underestimation, overestimation compared with non-corrected images) were compared. In PETMRAC images, a volume of interest was drawn in the area of the artefact and in a reference site (contralateral body part); the mean and maximum standardised uptake values (SUVmean; SUVmax) were measured. RESULTS Of 27 implanted materials (20 dental fillings, 3 injection ports, 3 hip prostheses and 1 sternal cerclage), 27 (100%) caused artefacts in CT, 19 (70%) in T1 weighted MRI and 17 (63%) in MRAC maps. 20 (74%) caused a visual overestimation of the (18)F-FDG uptake in PETCTAC, 2 (7%) caused an underestimation and 5 (19%) had no effect. In PETMRAC, 19 (70%) caused spherical extinctions and 8 (30%) had no effect. Mean values for SUVmean and SUVmax were significantly decreased in artefact-harbouring sites (p<0.001). CONCLUSION Contrary to PET attenuation correction artefacts in PET/CT, which often show an overestimation of the (18)F-FDG uptake, MRAC artefacts owing to implanted medical materials in most cases cause an underestimation. ADVANCES IN KNOWLEDGE Being aware of the morphology of artefacts owing to implanted medical materials avoids interpretation errors when reading PET/MRI.

Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients

Background The diagnostic accuracy of FDG-PET/CT for the detection of axillary lymph node metastases in breast cancer patients acquired 60 min after FDG administration is reported to be only moderate, especially due to low sensitivity. Purpose To test whether a delayed scan 90 min after FDG administration could enhance the diagnostic accuracy of FDG-PET/CT for the detection of axillary lymph node metastases. Material and Methods Thirty-eight women suffering from primary breast cancer (mean age 52 years; range 25–78 years; standard deviation 14 years) underwent a pre-therapeutic dual-time-point FDG-PET/CT scan. The maximum standardized uptake value (SUVmax) of axillary lymph nodes was measured at two different time points (time point T1: 60 min after FDG injection, time point T2: 90 min after FDG injection). SUVmax of axillary lymph nodes at T1 and T2 were assessed for statistical significance using a paired Wilcoxon-Test (P < 0.05). At T1 a qualitative analysis of the FDG-PET/CT scan was performed to define physiologic and metastatic lymph nodes. At T2 an increase of the SUVmax of at least 3.75% over time was rated as indicating malignancy. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the accuracy of FDG-PET/CT for the detection of axillary lymph node metastases was calculated at time points T1 and T2. Statistically significant differences were determined using Fishers exact test (P < 0.05). Histopathology served as the standard of reference. A compartment based analysis was done. Results Axillary lymph nodes had a mean SUVmax of 1.6 (range 0.6–10.8; SD 1.9) at T1 and a mean SUVmax of 1.8 (range 0.5–17.9; SD 3.5) at T2. This difference was statistically significant (P = 0.047). The sensitivity, specificity, PPV, NPV, and accuracy of FDG-PET/CT for the detection of axillary lymph node metastases was 81%, 100%, 100%, 88%, and 92% at T1, and 88%, 50%, 56%, 85%, and 66% at T2, respectively. This difference was not statistically significant (P = 0.27). Conclusion There is a slight increase of the FDG accumulation of axillary lymph nodes between 60 and 90 min after FDG administration. This increase did not translate into a statistical significant enhancement of the diagnostic accuracy of FDG-PET/CT for the detection of axillary lymph nodes. Especially due to false-positive results a delayed FDG-PET/CT scan 90 min after FDG administration is not able to enhance the diagnostic accuracy for the detection of lymph node metastases.

Transarterial Hepatic Chemoperfusion of Uveal Melanoma Metastases: Survival and Response to Treatment

PURPOSE To assess the survival of patients with hepatic uveal melanoma metastases undergoing sequential transarterial hepatic chemoperfusion. MATERIALS AND METHODS 61 patients (mean age, 60.3 ± 13.8 y) underwent a total of 249 hepatic chemoperfusion procedures (mean: 4 chemoperfusion procedures; range, 1-7 chemoperfusion procedures; standard deviation, 2.3 chemoperfusion procedures). All patients started with melphalan. In the case of progressive disease, melphalan was replaced by a different chemoperfusion agent. 38 patients were treated with melphalan only, 23 patients were treated with a combination of melphalan and other drugs. The median overall survival time was calculated for the overall population and several sub-groups. Differences in the survival rate between the sub-groups were assessed for statistical significance. The complication rate was assessed. RESULTS The median overall survival of the entire population was 10 months. The patients in the subgroups with a maximum number of 9 hepatic metastases as well as the patients in the subgroup without extrahepatic metastases at the beginning of therapy survived significantly longer than patients with more than 9 metastases/extrahepatic metastases (p = 0.019, p = 0.008). One patient (0.4%) died from liver failure after initial infusion of melphalan. CONCLUSION Intraarterial sequential hepatic chemoperfusion offers a minimally invasive treatment in patients with hepatic uveal melanoma metastases with good survival times and an acceptable major complication rate.

Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization.

PURPOSE To retrospectively assess the accuracy of angiography-based C-arm CT for the detection of extrahepatic shunting before SIRT. MATERIALS AND METHODS 30 patients (mean age: 64+/-12 years) with hypervascularized hepatic tumors underwent hepatic angiography, coil embolization of gastrointestinal collaterals and 99mTc-macroaggregated albumin (MAA) SPECT/CT before SIRT. Before MAA injection via a microcatheter from the intended treatment position, an angiography and angiography-based C-arm CT (XperCT, Philips Healthcare) were acquired. Angiographies and XperCT were performed from 48 microcatheter positions followed by MAA injections and MAA-SPECT/CT. MAA-SPECT/CT served as the reference standard for determining the accuracy of hepatic arteriography and C-arm CT for the detection of extrahepatic shunting. RESULTS MAA-SPECT/CT revealed extrahepatic shunting in 5 patients (17%). Hepatic arteriography yielded a true negative in 22 (73%), a false negative in 5 (17%), and an unclear result in 3 patients (10%). C-arm CT yielded a true positive in 3 (10%), true negative in 24 (80%), false positive in 1 (3%), and false negative in 2 patients (7%). The specificity and the NPV of hepatic arteriography for the detection of extrahepatic shunting were 88% and 81%, respectively. For C-arm CT the sensitivity, specificity, PPV, NPV, and accuracy for the detection of extrahepatic shunting were 60%, 96%, 75%, 92%, and 90%, respectively. CONCLUSION C-arm CT offers additional information to angiography when assessing SIRT patients for extrahepatic shunting. More accurate detection of extrahepatic shunting may optimize the workflow in SIRT preparations by avoiding unnecessary repeat angiographies.

Highly Iodinated Intravenous Contrast Material for PET/CT - a Feasibility Study

PURPOSE Intravenous contrast materials (CM) are of benefit in PET/CT imaging. However, CM may influence tracer quantification and may cause artifacts when using the CT data for PET attenuation correction. The aim of the study was to assess the feasibility of applying a highly concentrated CM (HCCM, 400 mg iodine/ml) in PET/CT in comparison to a lower concentrated CM (LCCM, 300 mg iodine/ml). MATERIALS AND METHODS In 60 whole-body FDG PET/CT scans (30 scans each with HCCM and LCCM), tracer uptake (maximal standardized uptake value - SUVmax) and CT attenuation (Hounsfield Units) were quantified at 16 positions in different vessels and parenchyma. The number of potential PET artifacts was documented. The Mann-Whitney-Wilcoxon Test was performed for statistical assessment (p < 0.05). RESULTS HCCM did not cause a significant increase in the SUVmax (p > 0.05) or the number of PET artifacts (p = 0.69) while simultaneously significantly increasing CT attenuation (p = 0.002) as compared to LCCM in 11 / 16 positions. CONCLUSION The application of HCCM seems feasible in PET/CT and should be considered in future protocols.

Selective internal radiotherapy (SIRT) for hepatocellular carcinoma

Microsphere-based radioembolization represents a new generation of therapeutics in interventional oncology. The intrahepatic application of radioactive microspheres via the hepatic artery allows locoregional therapy of diffuse or multifocal liver tumors, for which to date systemic therapy was the only remaining option. The current standard for this selective internal radiotherapy or radioembolization is yttrium-90 glass or resin microspheres. This review discusses the indications, the technique, and the therapeutic results of microsphere-based radioembolization.

Radioembolization of Hepatic Tumors: Flow Redistribution After the Occlusion of Intrahepatic Arteries

PURPOSE Radioembolization using 90yttrium is an emerging therapy option for unresectable liver malignancies. In order to reduce the number of yttrium injections, endovascular occlusion of a segmental hepatic artery has been proposed. The aim of this study was to assess whether sufficient vascular redistribution of the occluded liver segments through intrahepatic collaterals can be observed. MATERIALS AND METHODS 27 patients with hepatocellular carcinoma (n = 16) or hepatic metastases (n = 11) were studied. Hepatic angiography was performed on average 16 days prior to radioembolization. The segment II/III artery (n = 9) or the segment IV artery (n = 18) was occluded using coils. Technectium-99m-labeled macroaggregated albumin (99mTc-MAA) was injected into the right and the remaining part of the left hepatic artery in order to identify any hepatic volume not included in the perfused area. Patients underwent a SPECT/CT on average 1 h after the 99mTc-MAA injection. Two radiologists evaluated the SPECT/CT scans regarding the presence of non-perfused hepatic segments. Furthermore, hepatic perfusion was assessed by digital subtraction angiography (DSA) on the day of radioembolization. RESULTS In 16/27 patients (59%) a perfusion of the occluded liver segment was visible on the SPECT/CT scan. In 8/11 patients without flow redistribution at the time of the SPECT/CT, perfusion of the occluded segment through hepatic collaterals was observed during angiography prior to radioembolization. Hence, flow redistribution was eventually found in 24/27 patients (89%). CONCLUSION Flow redistribution after the occlusion of intrahepatic arteries prior to radioembolization can be successfully induced in the majority of patients with anatomical variants of the hepatic arteries.

Computer-Aided Detection (CAD) and Assessment of Malignant Lesions in the Liver and Lung using a Novel PET/CT Software Tool: Initial Results

PURPOSE To determine the feasibility of a PET/CT software tool (PET computer-aided detection: PET-CAD) for automated detection and assessment of pulmonary and hepatic lesions. MATERIALS AND METHODS 20 consecutive patients with colorectal liver metastases and 20 consecutive patients suffering from non-small cell lung cancer (NSCLC) were examined with FDG-PET/CT. In a first step the maximum standardized uptake values (SUV (max)) of non-tumorous liver and lung tissues were determined manually. This value was used as a threshold value for software-based lesion detection. The number of lesions detected, their SUV (max), and their sizes in the x, y, and z-planes, as automatically provided by PET-CAD, were compared to visual lesion detection and manual measurements on CT. RESULTS The sensitivity for automated detection was 96 % (86 - 99 %) for colorectal liver metastases and 90 % (70 - 99 %) for lung lesions. The positive predictive value was 80 % for liver and 68 % for lung lesions. The mean SUV (max) of all lung lesions was 9.3 and 8.8 for the liver lesions. When assessed by PET-CAD, the mean lesion sizes for liver lesions in the x, y, and z-planes were 4.3 cm, 4.6 cm, and 4.2 cm compared to 3.5 cm, 3.8 cm, and 3.6 cm for manual measurements. The mean lesion sizes of lung lesions were 7.4 cm, 7.7 cm, and 8.4 cm in the x, y, and z-planes when assessed by PET-CAD compared to 5.8 cm, 6.1 cm, and 7.1 cm when measured manually. Using manual assessment, the lesion sizes were significantly smaller in all planes (p < 0.005). CONCLUSION Software tools for automated lesion detection and assessment are expected to improve the clinical PET/CT workflow. Before implementation in the clinical routine, further improvements to the measurement accuracy are required.

MR-PET in Breast Cancer

Breast cancer is a common cancer entity in Western countries and represents a major public health problem. A specific therapy and, therefore, chance for and duration of survival is strongly dependent on the cancer stage, for which reason an accurate staging is indispensable. This chapter describes the use and limitations of whole-body MR-PET imaging for staging the primary tumor, locoregional lymph nodes, as well as distant metastases. A dedicated whole-body MR-PET protocol is introduced, considering specific demands of breast cancer patients, including MR-PET mammography. Moreover, aspects of MR imaging and functional FDG-PET are discussed with regard to restaging and treatment monitoring.